Table of Contents

• What is Acetazolamide?
• Normal Pressure Hydrocephalus: The Target Condition
• Research Objectives
• Potential Benefits of Acetazolamide
• Eligibility Criteria for the Study
• What the Study Will Measure
• Safety Considerations

What is Acetazolamide?

Acetazolamide Sodium, also known by its scientific name (5-ACETAMIDO-1,3,4-THIADIAZOL-2-YL)SULFONYLAZANIDE SODIUM, is a medication being studied for its potential in treating Normal Pressure Hydrocephalus (NPH)^[1]. It belongs to a class of drugs called carbonic anhydrase inhibitors, which affect certain processes in the body related to fluid balance.

Normal Pressure Hydrocephalus: The Target Condition

Normal Pressure Hydrocephalus is a condition where excess cerebrospinal fluid accumulates in the brain’s ventricles, causing various symptoms. It typically affects older adults and can lead to problems with walking, thinking, and bladder control^[1].

Research Objectives

A clinical trial is being conducted to investigate the effects of Acetazolamide in patients with NPH. The main goals of this research are:

1. To examine how Acetazolamide affects walking ability in NPH patients^[1].
2. To assess changes in patients’ symptoms and quality of life over time^[1].
3. To observe changes in brain imaging (MRI) parameters, focusing on:
   • White matter changes around the ventricles
   • Blood flow in the brain
   • Overall brain structure^[1]
4. To evaluate the safety and side effects of Acetazolamide in NPH patients^[1].
5. To measure changes in certain biological markers in blood and cerebrospinal fluid after treatment^[1].

Potential Benefits of Acetazolamide

While the full effects are still being studied, researchers hope that Acetazolamide may help improve symptoms of NPH, particularly:

• Walking ability: The study will closely monitor changes in gait (walking pattern) as a primary measure of the drug’s effectiveness^[1].
• Quality of life: Researchers will assess whether the medication leads to overall improvements in patients’ daily lives and well-being^[1].
• Brain health: The study will look at whether Acetazolamide can positively affect brain structure and function, as seen on MRI scans^[1].

Eligibility Criteria for the Study

To participate in this research, patients must meet specific criteria, including:

• Having a diagnosis of idiopathic (unknown cause) Normal Pressure Hydrocephalus^[1].
• Being between 50 and 82 years old^[1].
• Having adequate cognitive function (as measured by specific tests)^[1].
• Showing certain brain imaging features on MRI consistent with NPH^[1].

There are also several factors that would exclude a person from participating, such as certain medical conditions, medications, or inability to perform required tasks^[1].

What the Study Will Measure

To determine if Acetazolamide is effective, the researchers will look at several factors:

• Changes in walking ability, including:
  • Time and steps needed to walk 10 meters
  • Performance on a “timed up-and-go” test
  • Ability to walk backwards for 3 meters^[1]
• Quality of life assessments using questionnaires^[1].
• Changes in brain imaging results^[1].
• Overall changes in motor skills, thinking ability, and bladder control^[1].
• Levels of certain proteins in blood and cerebrospinal fluid that may indicate brain health^[1].

Safety Considerations

As with any medication, there are important safety considerations for using Acetazolamide:

• The study excludes people with allergies to Acetazolamide or similar drugs^[1].
• Certain medical conditions, such as kidney problems, liver issues, or heart failure, may prevent participation^[1].
• The medication may interact with other drugs, so some medications are not allowed during the study^[1].
• Pregnant women or those who may become pregnant are excluded for safety reasons^[1].

It’s important to note that this is an investigational use of Acetazolamide for NPH. The study aims to carefully monitor its effects and safety in this specific patient group^[1].